By: Cecil King
Canada Shows Missouri How To Be Smoke-Free And Thin
Scientific innovation continues to advance at breakneck speeds throughout the cannabis industry. While Missouri has not yet allowed its citizens to vote their preference for legal cannabis at the voting booth, other legal states are racing ahead developing state-of-the-art cannabis markets.
One of the fastest developing trends in the cannabis world is the rise of edibles or cannabis infused foods. Boulder-based BDS Analytics analyzed Colorado’s first quarter 2016 cannabis sales figures which showed a 67% increase in edible product sales for the February 2015 to February 2016 period.
However, edibles present the challenge of finding the right dosage for your comfort level.
Various factors can interfere with your expectations including how much food you’ve consumed before eating the edible, beverages you drank, your body mass index, and body metabolism. You’ll only know if your dosage choice is correct up to two hours after consuming the cannabis-infused food.
Now, two Canadian companies have agreed to join forces to offer a solution that solves many problems with edibles. It’s an Orally Dissolvable Thin Film (ODF) Wafer technology.
CanniMed Ltd., based in Saskatoon, SK, Canada will use CTT Pharmaceutical Holdings, Inc.’s patented wafer technology for a smoke-free, cannabis drug delivery system.
Orally Dissolvable Thin Film Wafers are paper-thin polymer films. These films infused with CanniMed® Oil products act as cannabinoid carriers. Administered orally, ODFs do not need water to dissolve. The wafer dissolves quickly in the oral cavity within 5-15 seconds.
The effect of the cannabinoids is almost immediate, more like smoking cannabis flowers. Active cannabinoids are rapidly absorbed into the dense network of blood capillaries via the thin oral mucosa in the mouth and throat. This method provides direct access to the bloodstream bypassing the intestinal tract and the up to two-hour wait a consumer must endure.
There is no bitter taste, no smoke inhalation, and less degradation of medication by bypassing the stomach. A higher absorption rate can lower dosage amounts.
The primary use is for medical cannabis patients. Providing medical cannabis patients “with dose-sensitive and discrete delivery systems will continue to place medical cannabis as an important therapeutic option for thousands of patients in Canada and the United States,” said CanniMed CEO, Brent Zettl. The companies announced their plans on August 23, 2016.
CanniMed Ltd. was the first cannabis producer licensed under the Marihuana for Medical Purposes Regulations in Canada and has the longest growing history as a result of the parent company, Prairie Plant Systems, Inc. The company was the sole supplier for the entirety of Health Canada’s former medical marijuana program.
Prairie Plant Systems has a strong corporate mission to design and execute clinical research on cannabis. It is the only licensed producer whose cannabis has already been used in two published clinical trials.
One randomized, controlled trial of smoked cannabis for a chronic neuropathic pain study found that a single inhalation of 25 mg of 9.4% THC herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep quality, reduced anxiety, and was well tolerated by patients.
The results of this study helped formulate the Canadian Pain Society’s Pharmacological Management policy on cannabis for chronic neuropathic pain.
The U.S. prohibits cannabis for any medical use and maintains it has no medical value and a high level abuse potential.